News and Insights

Defining and Demonstrating Value

Exchanges: Shaping the Consumer of the Future

eyeforpharma

The individual and SHOP (small business health options program) exchanges are getting significant media attention these days. When PPACA was enacted in 2010, one of its components was the creation of federal and state-based exchanges. The intent of these new marketplaces was to give more Americans access to affordable, quality…

Economic and Clinical Value: The Future of Cancer Care

Pharmaceutical Commerce

During the American Society of Clinical Oncology (ASCO) meeting earlier this year, a leading pharmaceutical company announced positive results for one of its drugs. For the first time in 10 years, a drug used to battle a recurrent cancer had been found to prolong life, in this case by more…

Will Biosimilars Meet the Market Similar Test?

eyeforpharma

The approval last year in the EU of generic Remicade represents a milestone of sorts. Biosimilars aim to replace, or at least compete with, products that generated over $100 billion in worldwide sales in 2013. While Europe has led the way in the development of a regulatory pathway for the…

Value Added Services: What It Takes to Do It Right

Numerof Brief

As a strategy to offset declining revenues, companies are testing a variety of initiatives focused on creating value added services (VAS) for drugs and medical devices. Disease management programs have been tried before by product manufacturers with limited success. This new wave differs from prior experiments in that it leverages…

Are De Facto Price Controls Imminent?

eyeforpharma

By and large the pharmaceutical industry has escaped price controls in the U.S. — especially when compared to other markets around the world.  Is this situation tenable, and if not, what will the implications be for the industry? Since 2003, Congress has prohibited Medicare from negotiating drug prices directly with…

Using Data to Link Product Value and Price

eyeforpharma

While the pharmaceutical and medical device industries have found themselves in a turbulent healthcare marketplace rife with changing regulations, new competitive challenges, and increasing pricing pressures, the end goal for manufacturers remains the same — product reimbursement and optimal pricing.  These two terms are regularly linked together because reimbursement is…